4578

Otsuka Holdings Co., Ltd. · TSE:4578

11,950.00 JPY180.00 +1.53%

Otsuka Holdings Co., Ltd. (TSE:4578) last traded at 11,950.00 JPY, up 1.53% on the day. Over the past year the stock is up 44.11%. Its 52-week range is 8,083.00 to 12,795.00. It is in the Health Technology sector (Pharmaceuticals: Major).

Key statistics

Open11,830.00

Day range11,735.00 – 12,040.00

52-week range8,083.00 – 12,795.00

Volume668.80 K

Average volume (10 days)1.28 M

Market cap (USD)38.93 B

P/E16.24

EPS (TTM) (USD)4.68

Dividend yield1.44%

Beta (1 year)0.3955

Revenue (TTM) (USD)17.11 B

Employees37.76 K

Performance

−3.08%1 week

+4.82%1 month

+0.72%3 months

+6.70%6 months

+33.91%Year to date

+44.11%1 year

Technical reading

Bullish

Daily summary of what 11 oscillators and 15 moving averages show. See every indicator

Latest headlines

Otsuka: Strong pharmaceutical growth lifted profit; FY2026 business profit guidance rose to ¥500bnQuartr · 30 Oct 2026
Otsuka Holdings 9M Results Rise; Lifts FY26 Earnings View, Backs Revenue Forecast; Stock Downdpa-AFX · 30 Oct 2026
Otsuka Holdings Co., Ltd. - To Retire Treasury Shares Worth 0.84% Of Outstanding Stock On December 11Reuters · 30 Oct 2026
Otsuka: Strong 9M growth lifted FY2026 profit guidance, while revenue guidance held steadyQuartr · 30 Oct 2026
Gujarat woos Japanese investors in Tokyo ahead of Vibrant Gujarat summit-2027Business Line · 21 Oct 2026
Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALSReuters · 22 Sep 2026
Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary EndpointReuters · 22 Sep 2026
Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung CancerReuters · 13 Sep 2026

Market data is delayed as each exchange requires (see data coverage). SuperCharting is charting software and gives no investment advice.